Kidney disease drug combo shows promise in small trial
NCT ID NCT04743739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding cyclosporine to rituximab is more effective than rituximab alone for treating idiopathic membranous nephropathy, a kidney disease that causes protein leakage. Only 12 adults with severe proteinuria took part before the study ended early. The goal was to see if the combination led to complete or partial remission, meaning less protein in urine and better blood protein levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality, 101149, China
-
Beijing Tongren Hospital， Capital Medical University
Beijing, Beijing Municipality, 100730, China
-
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100037, China
-
Nanyang Nanshi Hospital, Henan University
Nanyang, Henan, 473065, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054, China
-
The Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Shenzhen, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.